DS
SGMO

DRW Securities’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

DRW Securities’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,000
Closed -$150K – 467
2017
Q3 		$150K Buy
+10,000
New +$111K 0.05% 51

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DRW Securities's SGMO Position: Q4 2017 in Review

DRW Securities sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2017, closing a stake of 10,000 shares — an estimated $150K sold.

DRW Securities first reported a position in SGMO in Q3 2017 and held it in 1 quarter. The position peaked at $150K in Q3 2017. 170 funds tracked by Wall St. Rank hold SGMO as of Q4 2017.

  • DRW Securities reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2017 after selling out during the quarter.
  • DRW Securities sold 10,000 SANGAMO THERAPEUTICS INC shares in Q4 2017, an estimated $150K.
  • DRW Securities first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 1 quarter.
  • DRW Securities's SANGAMO THERAPEUTICS INC position peaked at $150K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2017.

Based on DRW Securities's 13F filing for Q4 2017, filed 14 Feb 2018.